ERBB2 and breast cancer: In the I-SPY 2 trial (NCT01042379), MK-2206 (135 mg/week) and anthracycline- or taxane-based neoadjuvant chemotherapy improved complete pathologic response in HER2 + and/or HR − breast cancer patients [96].